Select Page
Emer Leahy, Ph.D.

Emer Leahy, Ph.D.

Dr. Emer Leahy received her Ph.D. in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University. She is CEO of PsychoGenics Inc., a profitable preclinical CNS service company, and CEO of PGI Drug Discovery LLC, a company engaged in...
Thomas Oakley, BA, MBA

Thomas Oakley, BA, MBA

Tom is an accomplished senior executive with over 30 years of domestic and international leadership experience in contract research, industrial products and consumer products businesses, the last 25 years of which have been spent in the contract research industry. ...
David Bleakman, PhD

David Bleakman, PhD

David is an internationally recognized neuroscientist and expert in drug discovery and development who most recently held the position as Chief Scientific Officer of Redpin Therapeutics, a chemogenetics biotechnology company based in New York City, NY. Previously,...
Mark Varney, Ph.D.

Mark Varney, Ph.D.

Dr. Varney received his Ph.D. and post-doctoral training in Pharmacology from Oxford University, UK. He is Chief Scientific Officer of PsychoGenics, a preclinical CNS service company engaged in psychiatric drug discovery. Dr. Varney has more than 30 years of...
Dani Brunner, Ph.D.

Dani Brunner, Ph.D.

Dr. Brunner received her PhD at Cambridge University (UK), and post-doctoral training at Columbia University (USA). She joined PsychoGenics in 1999 where she developed preclinical tests for cognition, neurodegeneration, autism, between others. She conceived the...